Pfiz­er dou­bles down on Sang­amo’s zinc fin­ger tech, adding ALS to a mix of gene ther­a­py al­liances

What­ev­er Pfiz­er $PFE has learned about Sang­amo $SG­MO and its zinc fin­ger pro­tein tech­nol­o­gy for gene ther­a­pies in the 8 months since it signed off on a $545 mil­lion part­ner­ship on he­mo­phil­ia A seems to have on­ly en­cour­aged the phar­ma gi­ant to go deep­er — this time ex­pand­ing in­to neu­rol­o­gy.

This morn­ing the two com­pa­nies an­nounced plans to col­lab­o­rate on a new pro­gram for ALS, tar­get­ing mu­ta­tions of the C9ORF72 gene.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER